{"id":2144,"date":"2026-03-05T15:14:33","date_gmt":"2026-03-05T14:14:33","guid":{"rendered":"https:\/\/okuvision.de\/news\/pm-tes-gps\/"},"modified":"2026-04-30T12:05:10","modified_gmt":"2026-04-30T10:05:10","slug":"pm-tes-gps","status":"publish","type":"post","link":"https:\/\/okuvision.de\/en\/news\/pm-tes-gps\/","title":{"rendered":"Press release \u2013 Study protocol of the glaucoma study published in BMJ Open"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”0″ top_padding=”0″ bottom_padding=”0″ back_color=”color-206913″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ uncode_shortcode_id=”100151″ back_color_type=”uncode-palette”][vc_column width=”1\/1″]\n

\n \n \n
<\/div>\n \n \n
\n \n
\n
\n \n
\n \n Lesedauer ca. 3 Min. <\/span>\n \n 5. March 2026 <\/span>\n <\/div>\n \n

\n Press release <\/h1>\n \n
\n
\n

Open-access publication describes the design, endpoints and safety concept of the ongoing randomized pilot study at University Medical Center Mainz.
\n<\/em>Recruitment remains open.<\/em><\/p>\n <\/div>\n \n <\/div>\n \n

\n Company & Network<\/span>\n Research & Evidence<\/span>\n <\/div>\n \n <\/div>\n \n \n
\n \"Junge <\/div>\n <\/div>\n \n <\/div>\n \n<\/div>\n\n\n[\/vc_column][\/vc_row][vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″ content_parallax=”0″ uncode_shortcode_id=”959669″ row_name=”Einleitung”][vc_column column_width_percent=”70″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″ uncode_shortcode_id=”705359″][vc_custom_heading uncode_shortcode_id=”199860″]Study protocol published in BMJ Open: TES\u2011GPS investigates transcorneal electrical stimulation in open-angle glaucoma \u2013 recruitment is ongoing[\/vc_custom_heading][vc_column_text uncode_shortcode_id=”103565″]The study protocol for the TES\u2011GPS clinical trial on transcorneal electrical stimulation (TES) in open-angle glaucoma has now been published as an open-access article<\/a> in the journal BMJ Open. The publication describes the methodology of the ongoing study\u2014including study design, endpoints and blinding concept\u2014and is intended to create transparency and promote scientific discussion. At the same time, Okuvision, as sponsor, together with University Medical Center Mainz, points out that recruitment is still open: patients with demonstrably progressive visual field defects in open-angle glaucoma are welcome to enroll. <\/p>\n

Publishing a study protocol creates transparency how a clinical trial is planned: which patient group will be included, which examinations will be undertaken, which outcome measures will be assessed, and how bias can be reduced through randomization and blinding. A published protocol therefore strengthens the transparency of clinical research\u2014a key factor for trust among patients as well as for assessment by the professional community. <\/p>\n

Prof. Dr. Dr. Katrin Lorenz<\/strong>, Head of the Clinical Study Center at the Department of Ophthalmology and Polyclinic of University Medical Center Mainz and principal investigator of the study:
\n\u201cWith the protocol publication, we disclose the criteria by which we include patients, how the treatment is carried out, and which endpoints we assess. This is an important contribution to transparency\u2014and at the same time an invitation to draw the attention of suitable affected individuals to the possibility of participating in the study.\u201d<\/p>\n

Aim of the TES-GPS study: slowing the progression of visual field defects in addition to the standard of care<\/strong><\/p>\n

In glaucoma, lowering intraocular pressure is currently the central treatment option. Nevertheless, in some affected individuals the disease continues to progress despite treatment. The TES\u2011GPS study therefore investigates TES as an adjunct approach to potentially stabilize glaucoma-associated visual field defects for longer. <\/p>\n

In the study, TES is being evaluated using the OkuStim\u00ae 2 system. The therapy is administered once a week for 30 minutes and can\u2014after instruction\u2014be carried out at home. The study is designed as a single-center, randomized, double-masked, sham-controlled pilot study. <\/p>\n

Alfred Stett<\/strong>, CEO of Okuvision:
\n\u201cDespite established pressure-lowering therapies, glaucoma remains a major challenge for many affected individuals. As sponsor, we support the clinical trial of transcorneal electrical stimulation as an adjunct approach. What is crucial now is that a sufficient number of suitable patients take part\u2014only then can clinical research make progress possible.\u201d<\/p>\n

Who can participate?<\/strong><\/p>\n

The study is aimed at patients with open-angle glaucoma (e.g., primary open-angle glaucoma, PEX or pigment dispersion glaucoma, or normal-tension glaucoma) and demonstrably progressive visual field loss. Key requirements include, among others:<\/p>\n

 <\/p>\n